Table 1.
Comparisons of clinical characteristics of patients according to PRECISE-DAPT score (n = 552).
| Low-score (PRECISE-DAPT < 17, n = 210) | Intermediate score (PRECISE-DAPT 17–24, n = 87) | High score (PRECISE-DAPT ≥25, n = 255) | P-value | |
|---|---|---|---|---|
| PRECISE-DAPT score | 9.1 ± 5.3 | 20.9 ± 2.1** | 37.6 ± 11.1**†† | <0.001 |
| Age (years) | 55.9 ± 9.0 | 69.7 ± 5.5** | 76.4 ± 9.3**†† | <0.001 |
| Male gender (n, %) | 191 (91.0) | 67 (77.0) | 174 (68.2) | <0.001 |
| Body mass index (kg/m2) | 25.4 ± 3.7 | 23.8 ± 3.1** | 23.2 ± 3.6** | <0.001 |
| Current smoker (n, %) | 169 (80.5) | 55 (63.2) | 139 (54.5) | <0.001 |
| Co-morbidity or previous history | ||||
| Hypertension (n, %) | 169 (80.5) | 72 (82.8) | 216 (84.7) | 0.485 |
| Diabetes (n, %) | 109 (51.9) | 38 (43.7) | 127 (49.8) | 0.434 |
| Dyslipidemia (n, %) | 205 (97.6) | 83 (95.4) | 228 (89.4) | 0.001 |
| Chronic kidney disease (n, %) | 33 (15.7) | 35 (40.2) | 143 (56.1) | <0.001 |
| Anemia (n, %) | 41 (19.5) | 36 (41.4) | 167 (65.5) | <0.001 |
| Atrial fibrillation (n, %) | 17 (8.1) | 10 (11.5) | 53 (20.8) | <0.001 |
| Previous MI (n, %) | 11 (5.2) | 4 (4.6) | 20 (7.8) | 0.398 |
| Previous PCI (n, %) | 12 (5.7) | 6 (6.9) | 287 (11.0) | 0.108 |
| Previous CABG (n, %) | 0 (0.0) | 0 (0.0) | 6 (2.4) | 0.029 |
| Laboratory data | ||||
| White blood cell (/μL) | 6767 ± 2087 | 6332 ± 1722 | 6305 ± 2318 | 0.055 |
| Hemoglobin (g/dL) | 13.7 ± 1.4 | 12.8 ± 1.4** | 11.4 ± 1.8**†† | <0.001 |
| Creatinine clearance (mL/min) | 93.7 ± 22.8 | 67.4 ± 16.2** | 49.4 ± 20.4**†† | <0.001 |
| Echocardiography | ||||
| LVEF (%) | 49.3 ± 17.7 | 49.5 ± 16.6 | 47.1 ± 19.8 | 0.361 |
| Lesion characteristics | ||||
| Number of diseased vessels | <0.001 | |||
| 1 vessel (n, %) | 125 (59.5) | 40 (46.0) | 93 (37.2) | |
| 2 vessels (n, %) | 49 (23.3) | 33 (37.9) | 87 (34.8) | |
| 3 vessels (n, %) | 33 (15.7) | 14 (16.1) | 68 (27.2) | |
| 0 vessel (n, %) | 3 (1.4) | 0 (0.0) | 2 (0.8) | |
| Unknown (n, %) | 0 (0.0) | 0 (0.0) | 5 (2.0) | |
| No-infarct LMT lesion (n, %) | 4 (1.9) | 4 (4.6) | 17 (6.8) | 0.043 |
| No-infarct CTO lesion (n, %) | 12 (5.7) | 8 (9.2) | 29 (11.4) | 0.102 |
| Culprit lesion | <0.001 | |||
| LAD (n, %) | 109 (51.9) | 43 (49.4) | 96 (37.6) | |
| LCx (n, %) | 30 (14.3) | 18 (20.7) | 32 (12.5) | |
| RCA (n, %) | 64 (30.5) | 24 (27.6) | 108 (42.4) | |
| LMT (n, %) | 4 (1.9) | 2 (2.3) | 12 (4.7) | |
| CSA (n, %) | 3 (1.4) | 0 (0.0) | 2 (0.8) | |
| STEMI (n, %) | 155 (73.8) | 71 (81.6) | 196 (76.9) | 0.346 |
| Peak CK (IU/L) | 1781 (671–3910) | 2143 (1110–4030) | 1566 (673–3335) | 0.099 |
| Peak CK-MB (IU/L) | 196 (49–375) | 236 (109–478) | 194 (63–381) | 0.103 |
| Therapies | ||||
| BMS (n, %) | 53 (25.2) | 16 (18.4) | 63 (24.7) | 0.417 |
| DES (n, %) | 137 (65.2) | 59 (67.8) | 160 (62.7) | 0.667 |
| POBA (n, %) | 10 (4.8) | 7 (8.0) | 13 (5.1) | 0.498 |
| CABG (n, %) | 3 (1.4) | 0 (0.0) | 5 (2.0) | 0.417 |
| No interventional therapy (n, %) | 6 (2.9) | 4 (4.6) | 12 (4.7) | 0.568 |
| Door to balloon time (min) | 85 (69–125) | 74 (59–129) | 104 (75–144) | 0.075 |
| Medications | ||||
| Antiplatelets (n, %) | 204 (97.1) | 86 (98.9) | 247 (96.9) | 0.608 |
| β-blockers (n, %) | 170 (81.0) | 75 (86.2) | 198 (77.6) | 0.212 |
| RAS inhibitors (n, %) | 190 (90.5) | 78 (89.7) | 213 (83.5) | 0.063 |
| Statins (n, %) | 191 (91.0) | 78 (89.7) | 196 (76.9) | <0.001 |
| Anticoagulants (n, %) | 34 (16.2) | 13 (14.9) | 57 (22.4) | 0.143 |
PRECISE-DAPT, the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; LMT, left main trunk; CTO, chronic total occlusion; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; RCA, right coronary artery; CSA, coronary spastic angina; STEMI, ST-elevated myocardial infarction; CK, creatine kinase; BMS, bare metal stent; DES, drug eluting stent; POBA, plain old balloon angioplasty; RAS, renin-angiotensin system.
*P < 0.05 and **P < 0.01 vs. low score group, †P < 0.05 and ††P < 0.01 vs. intermediate score group.